Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Assets (2016 - 2025)

Karyopharm Therapeutics' Current Assets history spans 14 years, with the latest figure at $103.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 34.08% year-over-year to $103.1 million; the TTM value through Dec 2025 reached $103.1 million, down 34.08%, while the annual FY2025 figure was $103.1 million, 34.08% down from the prior year.
  • Current Assets reached $103.1 million in Q4 2025 per KPTI's latest filing, up from $89.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $350.2 million in Q4 2022 to a low of $89.7 million in Q3 2025.
  • Average Current Assets over 5 years is $220.2 million, with a median of $237.8 million recorded in 2021.
  • Peak YoY movement for Current Assets: increased 27.05% in 2022, then plummeted 53.07% in 2025.
  • A 5-year view of Current Assets shows it stood at $275.6 million in 2021, then grew by 27.05% to $350.2 million in 2022, then plummeted by 33.2% to $233.9 million in 2023, then tumbled by 33.11% to $156.5 million in 2024, then crashed by 34.08% to $103.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Current Assets are $103.1 million (Q4 2025), $89.7 million (Q3 2025), and $97.9 million (Q2 2025).